Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies

Autor: Benítez-García, Cristina, Martínez-García, David, Kotev, Martin, Pérez-Hernández, Marta, Westermaier, Yvonne, Díaz, Lucía, Korrodi-Gregório, Luis, Fontova, Pere, Torres, Ana Aurora, Pérez-Tomás, Ricardo, García-Valverde, María, Quesada, Roberto, Soliva, Robert, Soto-Cerrato, Vanessa

Publikováno v: In Biomedicine & Pharmacotherapy January 2025 182

Identification of the atypical antipsychotic Asenapine as a direct survivin inhibitor with anticancer properties and sensitizing effects to conventional therapies.

Autor: Benítez-García C; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Molecular Signaling, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Martínez-García D; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Molecular Signaling, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Kotev M; Nostrum Biodiscovery, Av. de Josep Tarradellas, 8-10, Barcelona E-08029, Spain., Pérez-Hernández M; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Molecular Signaling, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Westermaier Y; Nostrum Biodiscovery, Av. de Josep Tarradellas, 8-10, Barcelona E-08029, Spain., Díaz L; Nostrum Biodiscovery, Av. de Josep Tarradellas, 8-10, Barcelona E-08029, Spain., Korrodi-Gregório L; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Fontova P; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Department of Chemistry, Universidad de Burgos, Burgos, Spain., Torres AA; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Molecular Signaling, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain., Pérez-Tomás R; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., García-Valverde M; Department of Chemistry, Universidad de Burgos, Burgos, Spain., Quesada R; Department of Chemistry, Universidad de Burgos, Burgos, Spain., Soliva R; Nostrum Biodiscovery, Av. de Josep Tarradellas, 8-10, Barcelona E-08029, Spain., Soto-Cerrato V; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Molecular Signaling, Oncobell Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. Electronic address: vsoto@ub.edu.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Dec 17; Vol. 182, pp. 117756. Date of Electronic Publication: 2024 Dec 17.